Beatriz Chanduvi, MD
Endocrinology, Diabetes & Metabolism · Bethesda, MDNPI 1770586109
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,887 of the $8,789 with a category attached, or 89.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,134, 8.5 times the $604 reported in 2019.
Across 310 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Lilly USA, LLC$1K
- Novo Nordisk$796
- Cequr Corporation$613
- Corcept Therapeutics$474
- Amgen$474
- plus $4K from 29 others
What the payments were for
- Travel & lodging$90210%
- Food & beverage$7,88790%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $1,413 |
| Lilly USA, LLC | 58 | $1,334 |
| Novo Nordisk | 34 | $796 |
| Cequr Corporation | 2 | $613 |
| Corcept Therapeutics | 16 | $474 |
| Amgen | 24 | $474 |
| Boehringer Ingelheim | 18 | $391 |
| Amneal Pharmaceuticals LLC | 17 | $333 |
| Sanofi-aventis U.S. LLC | 13 | $309 |
| Abbott | 14 | $299 |
| AbbVie | 8 | $288 |
| Insulet Corporation | 7 | $280 |
| Mannkind Corporation | 12 | $241 |
| AstraZeneca(2 entities) | 11 | $229 |
| Antares Pharma, Inc. | 7 | $195 |
| Tandem Diabetes Care, Inc. | 5 | $150 |
| Radius Health, Inc. | 6 | $113 |
| Xeris Pharmaceuticals, Inc. | 4 | $92 |
| Madrigal Pharmaceuticals | 3 | $90 |
| BETA Bionics, Inc. | 3 | $81 |
| Recordati_rare_diseases_inc. | 4 | $80 |
| Amphastar Pharmaceuticals, Inc. | 4 | $76 |
| Ascendis Pharma Endocrinology Inc | 3 | $66 |
| IBSA Pharma Inc. | 5 | $64 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Dexcom, Inc. | 2 | $50 |
| Johnson & Johnson | 2 | $45 |
| Bayer | 1 | $30 |
| BD | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$942
- CeQur Simplicity$613
- Omnipod$138
- Korlym$125
- Synthroid$113
- MOUNJARO$102
How this compares
$8,789 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $165,256 |
| JardianceEmpagliflozin | 48 | $59,047 |
| JanuviaSitagliptin Phosphate | 37 | $50,900 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $32,157 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $31,788 |
| MounjaroTirzepatide | 28 | $30,121 |
| TrulicityDulaglutide | 19 | $28,974 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $25,814 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $23,144 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $22,617 |
| RybelsusSemaglutide | 17 | $19,630 |
| SynthroidLevothyroxine Sodium | 226 | $15,654 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $14,455 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $9,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $8,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $796 | $184,886105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,334 | $59,09447 claims |
| Boehringer IngelheimJardiance | $391 | $59,04748 claims |
| AbbVieSynthroid | $288 | $15,654226 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $333 | $5,424391 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Bethesda
- Michael CollinsBethesda$92K
- Michael BologneseBethesda$71K
- Thanh HoangBethesda$50K
- Mihail ZilbermintBethesda$27K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.